You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

XARACOLL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Xaracoll, and when can generic versions of Xaracoll launch?

Xaracoll is a drug marketed by Innocoll Pharms and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-nine patent family members in twenty-three countries.

The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.

Summary for XARACOLL
International Patents:79
US Patents:2
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 125
Clinical Trials: 4
Patent Applications: 4,353
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in XARACOLL?XARACOLL excipients list
DailyMed Link:XARACOLL at DailyMed
Drug patent expirations by year for XARACOLL
Recent Clinical Trials for XARACOLL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Premier Research Group plcPhase 3
CmedPhase 3
InnocollPhase 3

See all XARACOLL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for XARACOLL

US Patents and Regulatory Information for XARACOLL

XARACOLL is protected by two US patents.

Patents protecting XARACOLL


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Innocoll Pharms XARACOLL bupivacaine hydrochloride IMPLANT;IMPLANTATION 209511-001 Aug 28, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Innocoll Pharms XARACOLL bupivacaine hydrochloride IMPLANT;IMPLANTATION 209511-001 Aug 28, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for XARACOLL

See the table below for patents covering XARACOLL around the world.

Country Patent Number Title Estimated Expiration
Eurasian Patent Organization 037396 МОДИФИЦИРОВАННЫЙ КОЛЛАГЕН (MODIFIED COLLAGEN) ⤷  Try a Trial
Turkey 201907156 ⤷  Try a Trial
Japan 6720279 ⤷  Try a Trial
Cyprus 1121568 ⤷  Try a Trial
Croatia P20210699 ⤷  Try a Trial
Spain 2645445 ⤷  Try a Trial
Slovenia 3536748 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.